China’s First ADC Secures Domestic Approval
Gastric Cancer Nod
RemeGen’s second approval after a green light for its lupus drug signals accelerating approvals for domestically-developed antibodies in China.
You may also be interested in...
Japan approves a batch of new products and indications, including Daiichi Sankyo's Enhertu in a high-need indication after a rapid review and Takeda's Zejula, which will be made available to selected patients before its reimbursement listing.
The China-based biopharma company is seeking up to $602.8m gross in its Hong Kong IPO.
Chinese CAR-T therapy developer raises new funds to progress pipeline in over-subscribed IPO which ranks as the third-largest globally in the biotech sector to date this year.